Health-related quality of life with adjuvant nivolumab vs. placebo after radical resection for high-risk muscle-invasive urothelial carcinoma: Results from the phase 3 checkmate 274 trial

被引：0

作者：

Gschwend, J. E.

Bajorin, D.

Galsky, M. ^{[1
]}

Broughton, E. ^{[2
]}

Braverman, J. ^{[2
]}

Koon, H. ^{[3
]}

Maira-Arce, M. ^{[4
]}

Hamilton, M. ^{[2
]}

Shi, L. ^{[5
]}

Guo, S. ^{[5
]}

Witjes, J. A. ^{[6
]}

机构：

[1] Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, Tisch Canc Inst, New York, NY 10029 USA

[2] Bristol Myers Squibb, Dept Worldwide Hlth Econ & Outcomes Res, Princeton, NJ USA

[3] Bristol Myers Squibb, Clin Dev, Princeton, NJ USA

[4] Bristol Myers Squibb, Worldwide Med, Princeton, NJ USA

[5] Evidera, Dept Evidence Synth Modeling & Commun, Waltham, MA USA

[6] Radboud Univ Nijmegen, Med Ctr, Dept Urol, Nijmegen, Netherlands

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

P0821

引用

页码：S1139 / S1140

页数：2